%0 Journal Article
%T Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
%A Alessandra Mendon£¿a Almeida Maciel
%A Carlos Eduardo Brand£¿o-Mello
%A F¨¢bio Marchon Le£¿o
%A Helio Rzetelna
%A Isabela Martins Becattini Pereira
%A Lucas Pereira Jorge de Medeiros
%A Luiz Eduardo Amorim Correa Lima Pires
%A Marcia Maria Am¨ºndola Pires
%A Mariana Derm¨ªnio Donadel
%A Mario Barreto Correa Lima
%A Renata Barboza Vianna Medeiros
%J Archive of "Osong Public Health and Research Perspectives".
%D 2018
%R 10.24171/j.phrp.2018.9.2.03
%X To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) + daclatasvir (DCV); SOF + DCV + ribavirin (RBV); SOF + simeprevir (SMV)
%K antiviral agents
%K hepatitis C
%K patient reported outcome measures
%K quality of life
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935141/